Communiqués Orexo AB

Actions

Marché Fermé - Nasdaq Stockholm 18:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
13,40 ^SEK	-2,47 %		+1,67 %	-55,48 %

30/09	Orexo soumet à nouveau à l’Administration américaine des denrées alimentaires et des médicaments (FDA) une demande révisée pour son traitement contre les surdoses d’opioïdes	MT
29/09	Orexo soumet à nouveau sa demande auprès de la FDA pour Izipry	FW

29/09	Orexo resubmits NDA for IZIPRY™ to the FDA, a high-dose rescue medication for opioid overdose	AQ
14/09	Orexo: FDA clearance to start pivotal programme	AQ
10/09	BARDA Supports Contract Modification extending the initial Development stage for the OX390 project to end of 2027	AQ
01/09	Fredrik Järrsten resigns as CFO of Orexo AB	AQ
31/08	Orexo: Highlights from DNB Carnegie’s Micro Cap Day	AQ
31/08	Orexo: Reaches a non-binding settlement with DOJ	AQ
31/08	Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice	AQ
17/07	Orexo: Weak Q2, with potential H2 catalysts nearing – Q2 review	AQ
16/07	Orexo : Audiocast (engelska)	PU
16/07	Orexo Q2 2026 Interim Report	AQ
09/06	Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships	AQ
19/05	Orexo: Promising early-stage data	AQ
19/05	Orexo announces positive outcome from an in-vivo study of OX390	AQ
07/05	Report from Orexo AB’s annual general meeting May 7 2026	AQ
29/04	Orexo: Better visibility, few near-term catalysts – Q1 review	AQ
28/04	Orexo : Earnings Call Q1 2026 (engelska)	PU
28/04	Orexo : Earnings Call Q1 2026	PU
28/04	Orexo : Q1 2026 Interim Report MASTER	PU
28/04	Orexo : Q1 2026 Interim Report 2026	PU
28/04	Orexo : Audiocast	PU
28/04	Orexo Q1 2026 Interim Report	AQ
21/04	Invitation to presentation of Orexo´s Q1 2026 Interim Report	AQ
31/03	Number of shares and votes in Orexo	AQ
30/03	Notice of Annual General Meeting of Orexo	AQ
27/03	Orexo : Sustainability Report 2025	PU